DOI: 10.1055/s-00000054

Pharmacopsychiatry

Ausgabe 06 · Volume 21 · November 1988 DOI: 10.1055/s-002-10153

Introduction

263
Müller-Oerlinghausen, B.; Pflug, B.: 15th AGNP-Symposium, Nuremberg, 1987

Psychotrophic Drug Utilization

264
Netter, Petra: Prescription of Drugs as Related to Environmental and Organismic Determinants of Drug Action

266
Linden, M.: Individual Aspects of Physician and Patient, and their Impact on the Prescription of Psychotropic Medication
268
Bauer, M.; Scherer, J.; Strauß, A.: Is Psychopharmacotherapy Symptom or Diagnosis Directed?
270
Barnas, C.; Fleischhacker, W. W.; Stuppäck, C.: Utilisation of Benzodiazepines in a University Hospital
272
König, W.; Rissom, R.; Kalfoglu, G.; Stein, A.; Reimer, F.: Long-term Therapy of Affective Disorders: Monotherapy or Polypharmacy?
274
Schmidt, St.; Ludwig, W.; Seibold, S.; Greil, W.: Prophylactic Lithium Treatment: Treatment Response, and Patient Attitudes toward Illness and Treatment
276
Koch, R.; Strauss, A.: The Course of Neuroleptic and Antidepressant Treatment in Severe Depressive Illness
293
Bürke, H.; Grohmann, R.; Rüther, E.: Drug Surveillance / Drug Monitoring in Psychiatric Out-Patient Treatment: Prescription of Psychotropic Drugs, Diagnoses and Adverse Drug Reaction - 3 Years
295
Classen, W.; Laux, G.: Sensorimotor and Cognitive Performance of Schizophrenic Inpatients Treated with Haloperidol, Flupenthixol, or Clozapine
298
Strauss, W. H.; Klieser, E.; Luethcke, H.: Dyscognitive Syndromes in Neuroleptic Therapy
300
Kuny, S.; Binswanger, U.: Ionized Calcium and Neuroleptic-induced Extrapyramidal Symptoms
302
Wagner, B.; Wolf, G. K.; Ulmar, G.: Does Smoking Reduce the Risk of Neuroleptic Parkinsonoids?
304
Möller, H. J.; Meier, K.; Wernicke, T.: Empirical Investigation on the Risk of Agranulocytosis/Leucopenia under Medication with Antidepressants
306
Sassim, N.; Grohmann, R.: Adverse Drug Reactions with Clozapine and Simultaneous Application of Benzodiazepines
308
Tegeler, J.; Strauss, W. H.; Lüthcke, H.; Bertling, R.: Cognitive Functions in Schizophrenic Patients with Tardive Dyskinesia
310
Kalserauer, Ch. H.; Komhuber, J.; Komhuber, A. W.; Bauer, K.: Alcohol Consumption, Blood-Cerebrospinal Fluid Barrier,and Guillain-Barré Syndrome
314
Havemann, Ursula: Does Individually Different Sensitivity to Dopaminergic Stimulation Determine the Degree of Tolerance and Dependence to Opioids?
317
Kuschinksy, K.; Möller, H.-G.; Novak, K.; Walter, S.: Conditioning of Signs of a Dopaminergic Stimulation in Rats
319
Rick-Brand, Sabine; Müller, W. E.: Direct and Indirect Effects of Alprazolam and Imipramine on α1-and α2-Adrenoceptors in Mouse Forebrain
321
Schubert, T.; Brunner, F.; Müller, W. E.: The Interaction of RS 86, a Centrally Acting m-Cholinoceptor Agonist with M1 and M2 Receptors in Rat Brain and Rat Heart, Respectively*
324
Pilch, H.; Müller, W. E.: Chronic Treatment with Piracetam Elevates Muscarinic Cholinergic Receptor Density in the Frontal Cortex of Aged Mice
326
Erfurth, A.; Reddington, M.; Schmauss, M.: Studies on Binding Sites for Adenosine Receptor Ligands in Rat Brain: An Approach to the Specification of Adenosinergic Functions
329
Hegerl, U.; Gaebel, W.; Ulrich, G.: Relationship Between Residual Symptomatology and Auditory Evoked Potentials in Schizophrenic Outpatients
331
Krieger, S.; Bertling, R.; Schweizer, A.; Tegeler, J.: Recording Automatic and Controlled Information Processing by Means of Bioelectrical Brain Signals in Normals and Paranoid Schizophrenics with and without Neuroleptic Medication
334
Mackert, A.; Woyth, C.; Flechtner, M.; Frick, K.: Increased Blink Rate in Acute and Remitted Schizophrenics
336
Hegerl, U.; Prochno, I.; Ulrich, G.; Müller-Oerlinghausen, B.: Are Auditory Evoked Potentials Suitable for Predicting the Response to Lithium Prophylaxis? - A study on the Effects of Repeated Measurement, Age, Gender, and Personality on the Amplitude/Stimulus Intensity Function in Healthy Volunteers*
338
Maurer, K.; Dierks, T.; Laux, G.; Rupprecht, R.; Ihl, R.: Topographic Mapping of EEG and Auditory Evoked P300 in Neuropsychopharmacology (Topographic Pharmaco-EEG and Pharmaco-AEP 300)
343
Ihl, R.; Maurer, K.; Dierks, T.; Wannemacher, W.: Effects of Pyritinol on the Distribution of Electrical Brain Activity
346
Reischies, F. M.; Gaebel, W.; Mielewczyk, A.; Frick, K.: Disturbed Eye Movements Guided by Visuospatial Cues in Schizophrenic Patients
348
Schulze, R. M.; Müller, W. E.; Gattaz, W. F.: A Radioenzymatic Assay for the Determination of Phospholipase A2 in Serum Suitable for Psychiatric and Non-Psychiatric Patients
353
Priebe, S.; Liesenfeld, O.; Müller-Oerlinghausen, B.: Resumption of Benzodiazepine Use After Withdrawal in Hospital - A Follow-up Study*
355
Barnas, C.; Fleischhacker, W. W.; Stuppäck, C.; Whiteworth, A. B.; Hinterhuber, H.: Investigation of Benzodiazepine-Consumers Concerning Intake-Habits,Signs of Abuse or Dependence, and Information About the Drug
357
Flechsenhar, K.; Müller, W. E.: Some Preliminary Data About the Properties of Tribulin, an Endogenous, Benzodiazepine Receptor Binding Inhibiting Compound from Human Urine
360
Martin, J. R.; Pieri, L.; Bonetti, E. P.; Schaffner, R.; Burkard, W. P.; Cumin, R.; Haefely, W. E.: Ro 16-6028: A Novel Anxiolytic Acting as a Partial Agonist at the Benzodiazepine Receptor
365
Meyer, J. W.; Woggon, B.; Küpfer, A.: Importance of Oxidative Polymorphism on Clinical Efficacy and Side-Effects of Imipramine - A Retrospective Study
367
UIrich, G.; Haug, H.-J.; Stieglitz, R.-D.; Fähndrich, E.: EEG Characteristics of Clinically Defined On-Drug-Responders and Non-Responders - A Comparison Clomipramine vs. Maprotiline
369
Stuppäck, Ch.; Schubert, H.; Barnas, Ch.; Mair, M.; Schifferle, I.; Unterweger, B.; Wörnhart, L.; Fleischhacker, W. W.; Hinterhuber, H.: First Results of an Open Phase II Study with the Antidepressant Paroxetine
371
Müller, W. E.; Bauer, K.; Rost, W.; Filser, J. G.; Fischer, M.; Gattaz, W. F.: Urinary MHPG-Sulfate and Urinary MHPG-Glucuronide, two Possible Markers of the Central or Peripheral Norepinephrine Metabolism in Man.The Effect of Alprazolam Treatment
374
Gattaz, W. F.; Bauer, K.; Rost, W.; Hübner, C. v K.; Müller, W. E.: Alprazolam Response in Major Depression: Relationship with Urinary Levels of MHPG-Sulfate
376
Frommberger, U.; Phllipp, M.; Maier, W.: The Influence of Medication on the Course of Major Depression: A 3-Year-Follow-Up with Polydiagnostic Measures
378
Laux, G.; Becker, T.; Kühne, G.; Lesch, K.-P.; Riederer, P.; Beckmann, H.: Clinical and Biochemical Effects of the Selective Phosphodiesterase Inhibitor Rolipram in Depressed Inpatients Controlled by Determination of Plasma Level
380
Phllipp, M.; Maier, W.: A Replication Study for the Prediction of Doxepine-Response in Depressed Outpatients
381
Filser, J. G.; Kaumeier, S.; Brand, T.; Schanz, H.; Terlinden, R.; Müller, W. E.: Pharmacokinetics of Amitriptyline and Amitriptylinoxide after Intravenous or Oral Administration in Humans
387
Gerbaldo, H.; Demisch, L.; Lehmann, C.-O.; Bochnik, J.: The Effect of OPC-4392, a Partial Dopamine Receptor Agonist on Negative Symptoms: Results of an Open Study
389
Olbrich, R.; Schanz, H.: The Effect of the Partial Dopamine Agonist Terguride on Negative Symptoms in Schizophrenics
391
Klieser, E.; StrauB, W. H.: Study to Establish the Indication for the Selective S2 Antagonist Ritanserin
394
Wetzel, H.; Heuser, I.; Benkert, O.: Benzodiazepines for Catatonic Symptoms, Stupor, and Mutism
396
Ruhland, M.; Krähling, H.; Fuchs, A.; Schön, U.: KC 9172* (Free Base of KC 7218) - An Antipsychotic/Anxiolytic Compound I. Antipsychotic and Anxiolytic Activity in Comparison with Chlorpromazine, Clozapine, Diazepam and Buspirone
399
Krähling, H.; Fuchs, A.; Ruhland, M.; Schön, U.; Mol, F.; Tulp, M.: KC 9172* (Free Base of KC 7218) - An Antipsychotic/Anxiolytic Compound II. Discrimiantion from Typical Neuroleptics and Benzodiazepine-like Minor Tranquilizers
402
Lesch, K. P.; Laux, G.; Pfüller, H.; Schulte, M.: Alpha-Adrenoceptor Function in Acute Paranoid Schizophrenia
407
Fähndrich, E.; Haug, H.-J.: Delusional Depression - A Distinct Illness?
410
Fey, P.; Pflug, B.; Jost, K.: Self-Rating of the Global State of Mood of Depressive Patients by a Bright-Dark-Scale
412
Stieglitz, R.-D.; Haug, H.-J.; Fähndrich, E.: Comparison Between Types of Diurnal Variations as Determined by Global Assessment and Daily Recordings of Mood
414
Fleischhauer, J.; Glauser, G.; Hofstetter, P.: The Influence of Light Therapy in Depressive Patients
416
Schlegel, Sabine; Maier, W.; Philipp, M.; Heuser, Isabella; Aldenhoff, J.: The Association between Psychopathological Aspects and CT Measurements in Affective Disorders
418
Haug, H.-J.; Fähndrich, E.: A Turning Point for Mood during Sleep Deprivation Therapy -does it Exist?
420
Demisch, L.; Gerbaldo, H.; Demisch, K.: Fluvoxamine-Melatonin-Stimulation-Test (FMST) in Patients with Depressive Disorders
422
Buller, R.; Maier, W.; Philipp, M.: Reliability of DSM-III Anxiety Disorders - Check-List Versus Structured Interview
424
Frommberger, U.; Philipp, M.; Maier, W.; Buller, R.; Klingler, T.: Prediction of Course in Major Depression. Does Psychopathology Predict Future Drug Intake or Relapse?
426
Volk, J.; Müller-Oerlinghausen, B.: Quality of Interepisodic Periods in Patients with Affective Disorders under Long-Term Lithium Treatment
428
Kasper, S.; Rogers, S. L.; Yancey, A. L.; Schulz, P. M.; Skwerer, R. G.; Rosenthal, N. E.: Phototherapy in Subsyndromal Seasonal Affective Disorder (S-SAD) and "Diagnosed" Controls
430
Lesch, K. P.; Laux, G.; Schulte, H. M.; Erb, A.; Pfüller, H.; Beckmann, H.: Pre- and Postsynaptic Alpha-Adrenergic Effects of Clonidine in Major Depressive Disorder
432
Carl, C.; Engelhardt, W.; Teichmann, G.; Fuchs, G.: Open Comparative Study with Treatment-Refractory Depressed Patients: Electroconvulsive Therapy - Anesthetic Therapy with Isoflurane (Preliminary Report)
434
van Calker, D.; Steber, R.; Greil, W.: Effects of Lithium Ions on the Metabolism of Inositol Phospholipids: Studies with Human Granulocytes
436
Fritze, J.; Koronakis, P.; Riederer, P.; Hekman, M.: Lymphocyte Adenylate Cyclase: A Model for Putative Adrenergic-Cholinergic Imbalances in Affective Disorders?
438
Rupprecht, R.; Rupprecht, Chr.; Rupprecht, M.; Noder, Monika; Schwarz, W.: Different Reactivity of the Hypothalamo-Pituitary-Gonadal-Axis in Depression and Normal Controls
440
Lesch, K.-P.; Laux, G.; Erb, A.; Pfüller, H.; Beckmann, H.: Neuroendocrine Regulation of Growth Hormone Secretion in Major Depressive Disorder
443
Neuhauser, H.; Laakmann, G.: Stimulation of Growth Hormone by GHRH as Compared to DMI in Depressed Patients
445
Hinz, A.; Laakmann, G.; Kropp, F.; Dick, G.: Influence of Growth Hormone Releasing Hormone (GHRH) on the Growth Hormone (GH) Secretion in Healthy Female and Male Subjects
447
Kohnen, R.; Oswald, W.-D.: The Effects of Valerian, Propranolol, and their Combination on Activation, Performance, and Mood of Healthy Volunteers under Social Stress Conditions
451
Stieglitz, R.-D.; Fähndrich, E.; Renfordt, E.: Interrater Study for the AMDP System
453
Huber, D.; Henrich, G.; Herschbach, P.: Measuring the Quality of Life: A Comparison between Physically and Mentally Chronically III Patients and Healthy Persons
456
Schönell, H.: Efficiency of the AMDP Anamnestic Data in Psychiatric Research
458
Albrecht, J.; Hedde, H. P.; Lundt, A.; Pittlik, V.; Stieglitz, R.; Baranowski, E.: Psychopathometrlcs in HIV-infected Patients - A Multimethodologic Study
459
Steinwachs, K. C.; Fehm, H. L.: Effects of the Neuropeptide PLG (L-Prolyl-leucyl-glycinamide) on Writing Pressure and Speed in Healthy Subjects
461
Huber, Dorothea: Combined and Separate Treatment Effects of Nicotine Chewing Gum and Self-Control Method
463
Hebenstreit, Marina; Buller, R.; Maier, W.; Philipp, M.; Frommberger, U.: The Personality Sphere in Patients with Panic Attacks
465
Philipp, M.; Delmo, Cynthia; Maier, W.; Buller, R.: The Use of Research Assistants in Polydiagnostic Research

Workshop I

278
Böcker, F. M.; Busch, H.; Feuerlein, W.; Mann, K.; Poser, W.; Rommelspacher, H.; Schied, H. W.; Thaden, A.: Projects of Biomedical Research on Alcoholism

Workshop II

281
Philipp, M.; Maier, W.; Buller, R.: Pharmacotherapy of Panic Attacks

Workshop III

283
Riederer, P.; Laux, G.; Beckmann, H.; Saletu, B.; Waldmeier, P.; Fritze, J.; DaPrada, M.; Möller, H. J.; Schmauss, M.; Przuntek, H.: The New Generation of Selective Monoamine Oxidase-lnhibitors: Biochemical, Pharmacological and Clinical Perspectives

Workshop IV

285
Möller, H. J.; Kissling, W.; Baumann, W.; Breyer-Pfaff, U.; Delini-Stula, A.; Holsboer, F.; Jungkunz, G.; Kuhs, H.; Laux, G.; Müller, W. E.; Müller-Oerlinghausen, B.; Schmauss, M.; Schönbeck, G.; Steiger, A.; Woggon, B.: Non-Response to Antidepressants: Risk Factors and Therapeutic Possibilities

Workshop V

288
Janke, W.; Kallus, W.; Netter, Petra: Psychopharmacological Acute Trials: Methodological Problems and Approaches for Solutions

Adverse Drug Reactions

290
Spieß-Kiefer, C.; Grohmann, R.; Schmidt, L. G.; Rüther, E.: Severe and Life-Threatening Adverse Reactions to Psychotropic Drugs

Effects of Psychotropic Drugs:Models in Animals

312
Coward, D. M.; Dixon, A. K.; Urwyler, S.; Vigouret, J.-M.: Pharmacological Properties of SDZ 208-912: A Potential High Potency,Non-Classical Neuroleptic

Benzodiazepines

350
Pohl, J.; Janke, W.; Erdmann, G.; Capek, D.: The Problem of Influencing Specific or Unspecific Emotional States by Drugs: Effects of a Tranquilizer and Two Beta-Blocking Agents under Noise Conditions

Antidepressant Drugs

363
Möller, H. J.; Haug, G.: Secondary and Meta-Analysis of the Efficacy of Non-Tricyclic Antidepressants

Therapy of Schizophrenia

384
Gaebel, W.; Pletzcker, A.; Ulrich, G.; Schley, J.; Müller-Oerlinghausen, B.: Predictors of Neuroleptic Treatment Response in Acute Schizophrenia: Results of a Treatment Study with Perazine

Depression:Models and Methods in Clinical Research

404
Kaschka, W. P.; Thürauf, N.; Mokrusch, Th.; Korth, M.: Electrooculography and Dark Adaptation in Patients with Affective and Schizoaffective Psychoses: Early Physiological Effects of Carbamazepine and Lithium

Psychopayhometry

449
Maier, W.; Philipp, M.; Buller, R.; Schlegel, S.: Reliability and Validity of the Assessment of Antidepressant Effects